Furthest along
2 in Phase 3
1 in Phase 2
Drugs
4
in active trials · 7 in all
Trials
9 active
14 since 2021
Drugs4
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 3 | 1 May 2030Phase 3 trial completes | |||
| Next date | 1 May 2030 · Phase 3 trial completes | ||||
| Also tested for | Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia and 2 more | ||||
| Open drug page | |||||
ALK/ROS1 inhibitor |
Phase 3 | — | |||
| Also tested for | Non-small Cell Lung Cancer, Non Small Cell Lung Cancer | ||||
| Open drug page | |||||
— |
Phase 1/2 | — | |||
| Also tested for | Hematologic Malignancy, Non Hodgkin Lymphoma and 3 more | ||||
| Open drug page | |||||
— |
Phase 1 | Feb 2027Phase 1 trial completes | |||
| Next date | Feb 2027 · Phase 1 trial completes | ||||
| Also tested for | Non Small Cell Lung Cancer, Advanced Solid Tumor and 1 more | ||||
| Open drug page | |||||
About
- No active trial
- cycle 1: reference drug, cycle 2: reference drug, cycle 3: reference drug
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021